Gene Repair Markers May Predict Breast Cancer Chemotherapy Response
New research identifies nucleotide excision repair deficiency biomarkers that could help select triple-negative breast cancer patients for platinum-based chemotherapy.
Updated on Nov. 16, 2026 in Cancer

Researchers report biomarkers linked to nucleotide excision repair deficiency that may identify triple-negative breast cancer patients likely to respond to platinum-based chemotherapy. The findings, published in Npj Breast Cancer, suggest the approach could identify patients beyond those detected by existing homologous recombination deficiency testing.
Why it matters
Existing homologous recombination deficiency testing has shown only modest predictive ability in clinical trials, leaving room for better tools to guide treatment decisions. Combining biomarkers that assess different DNA repair pathways could improve prediction of platinum response in this aggressive cancer type.
The study analyzed 943 cases in the Cancer Genome Atlas breast cancer cohort, with 4.7% showing nucleotide excision repair deficiency without homologous recombination deficiency, while the ERCC2mut score and HRDetect were each associated with pathological response in 50 cisplatin-treated patients. The ERCC2mut score was originally developed using bladder cancers, and further validation in breast cancer is still required.
The details
The team applied an ERCC2mut score, developed using bladder cancers with inactivating ERCC2 mutations, to assess nucleotide excision repair deficiency in breast cancer. In a trial of 54 patients treated with cisplatin and 45 treated with paclitaxel, several repair-deficiency mutational signatures were significantly associated with response in the cisplatin group only, and the two biomarkers identified largely different patient groups.
Timeline
Npj Breast Cancer published the study in 2026.
Health Landscape
Current biomarker testing for platinum response in triple-negative breast cancer relies heavily on homologous recombination deficiency testing, which has shown only modest predictive power in clinical trials. This research points toward assessing multiple DNA repair pathways together as a route to more precise treatment selection.
For people with triple-negative breast cancer, these biomarkers could eventually help clinicians decide whether platinum-based chemotherapy is likely to work before treatment begins. The findings are early, however, and current treatment decisions remain unchanged until the markers are validated.
The takeaway
Testing for multiple DNA repair deficiencies, rather than one pathway alone, may give oncologists a more complete picture of which patients will benefit from platinum chemotherapy. Patients should discuss current biomarker options with their oncology team.
Further reading
For more on how doctors are treating these tumors, explore our Cancer coverage.
More information
Read the full Npj Breast Cancer study on nucleotide excision repair deficiency for complete methods and results.



